Our finding that ITA/OXGR1 signaling could boost MCC of inhaled pathogens not only reveals a mechanism explaining how the barrier function of the airway is upregulated by innate immune cells during infection, but also identifies OXGR1 as a potential target for developing a synthetic ITA mimic compound to treat mucus clearance defects. This evidence concerns the gene OXGR1 and infection.